Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 63
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2559-2569
Open Access | Times Cited: 60
Advances in artificial intelligence to predict cancer immunotherapy efficacy
Jindong Xie, Xiyuan Luo, Xinpei Deng, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 54
Thermophoretic glycan profiling of extracellular vesicles for triple-negative breast cancer management
Yike Li, Shaohua Zhang, Chao Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 16
Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy
Jay Chadokiya, Kai Chang, Saurabh Sharma, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Ying‐Chun Shen, Tsung‐Hao Liu, Alan Nicholas, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4060-4070
Closed Access | Times Cited: 5
Utopia 2070
Saina Adiban Afkham, Soroush Mirdehghan
(2025), pp. 1-17
Closed Access
Circulating biomarkers for diagnosis, prognosis, and treatment response prediction in cancer
Lorenzo Galluzzi, Sheila Spada
International review of cell and molecular biology (2025), pp. xiii-xvii
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Discovery of a DNA repair-associated radiosensitivity index for predicting radiotherapy efficacy in breast cancer
Jianguang Lin, Hainan Yang, Rongfu Huang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Akhilesh Mishra, Dhiraj Kumar, Kuldeep Gupta, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 581-591
Open Access | Times Cited: 19
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Joseph C. Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 2, pp. 389-403
Open Access | Times Cited: 12
A muti-modal feature fusion method based on deep learning for predicting immunotherapy response
Xiong Li, Xuan Feng, Juan Zhou, et al.
Journal of Theoretical Biology (2024) Vol. 586, pp. 111816-111816
Closed Access | Times Cited: 4
A Review of Immunotherapy for Head and Neck Cancer
Joëlle Goetz, Guilherme Rabinowits, Noah S. Kalman, et al.
Journal of Dental Research (2024) Vol. 103, Iss. 12, pp. 1185-1196
Closed Access | Times Cited: 4
Local Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer
Qian Chen, Yanan Li, Jiameng Hu, et al.
Advanced Science (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 3
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
H. N. Abramson
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15674-15674
Open Access | Times Cited: 7
Precision Immuno-Oncology in NSCLC through Gender Equity Lenses
Jennifer A. Marks, Arthi Sridhar, Angela Ai, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1413-1413
Open Access | Times Cited: 2
Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients
Sebastian Sommer, Maximilian Schmutz, Kathrin Hildebrand, et al.
Journal of Laboratory Medicine (2024) Vol. 48, Iss. 3, pp. 107-119
Open Access | Times Cited: 2
ImmunoPET imaging of LAG-3 expression in tumor microenvironment with68Ga-labelled cyclic peptides tracers: from bench to bedside
Ming Zhou, Bei Chen, Chenxi Lu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e009153-e009153
Open Access | Times Cited: 2
Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations
Maha Aldoughaim, Nada Alsuhebany, Mohammed Alzahrani, et al.
Clinical Medicine Insights Oncology (2024) Vol. 18
Open Access | Times Cited: 2
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)
Xinghao Ai, Bo Jia, Zhiyi He, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
Paola Trono, Annalisa Tocci, Belinda Palermo, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006913-e006913
Open Access | Times Cited: 5
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
H. N. Abramson
(2023)
Open Access | Times Cited: 5
Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer
Wen‐Cheng Chou, Wei‐Ting Chen, Chun‐Tse Kuo, et al.
Cell Reports (2023) Vol. 43, Iss. 1, pp. 113641-113641
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top